Chimeric molecule, pharmaceutical composition, target nucleic acid cleavage method, and target nucleic acid cleavage or diagnosis kit

Through the binding of chimeric molecules and nucleases, efficient cleavage of target RNA is achieved at low concentrations, solving the problem of difficulty in inhibiting target nucleic acid drugs at low concentrations, reducing off-target effects, and improving treatment effect.

CN114144525BActive Publication Date: 2024-11-12TOHOKU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080052437.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-24
Filing Date
2020-07-22
Publication Date
2024-11-12
Estimated Expiration
2040-07-22

AI Technical Summary

Technical Problem

It is difficult for existing nucleic acid drugs to effectively inhibit target nucleic acid at low concentrations, resulting in off-target effects and affecting the therapeutic effect.

Method used

Design a chimeric molecule, which is fused by the first nucleic acid that has the ability to bind to the target nucleic acid and the second nucleic acid whose main chain backbone is anionic, and through rapid dissociation after nuclease cleavage, improves the efficiency of RNA enzymes to cleave target RNA. Reduce off-target effects.

Benefits of technology

The function of inhibiting target nucleic acid at low concentrations is achieved, the off-target effect is reduced, the efficiency of RNA enzyme cleavage target RNA and the therapeutic effect is enhanced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0004892584090000061
    Figure GDA0004892584090000061
  • Figure GDA0004892584090000071
    Figure GDA0004892584090000071
  • Figure GDA0004892584090000081
    Figure GDA0004892584090000081
Patent Text Reader

Abstract

The present invention relates to a chimeric molecule, a pharmaceutical composition comprising the chimeric molecule, a method for cleaving a target nucleic acid using the chimeric molecule, and a kit for cleaving or diagnosing a target nucleic acid comprising the chimeric molecule. The chimeric molecule is a fusion of a first nucleic acid or a derivative thereof having a binding ability to a target nucleic acid and a second nucleic acid or a derivative thereof having a binding ability to the target nucleic acid and an anionic main chain skeleton.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a chimeric molecule, a pharmaceutical composition, a method for cleaving a target nucleic acid, and a kit for cleaving or diagnosing a target nucleic acid.

[0002] This application claims priority based on Japanese Patent Application No. 2019-136414 filed in Japan on July 24, 2019, and the contents are incorporated herein by reference. Background Art

[0003] In recent years, nucleic acid drugs, like antibody drugs, have attracted attention as next-generation molecular targeted drugs. In particular, nucleic acid drugs are also involved in diseases that cannot be treated with antibody drugs. In addition, they have many advantages such as being relatively cheap through chemical synthesis, and like antibody drugs, their status as post-low molecular drugs is gradually being established.

[0004] Nucleic acid drugs have reported various drug strategies, such as antisense nucleic acids (ASOs) that target messenger RNA (mRNA), microRNA (miRNA), small interfering RNA (siRNA), etc. that are related to disease progression, selectively recognize base sequences, form complexes, and thus inhibit the function of target RNA to exert therapeutic effects. In order for these nucleic acid drugs to effectively exert their efficacy, 1) high in vivo stability and 2) high specificity for the target nucleic acid and complex stability are required, and the development of oligonucleotides / artificial oligonucleotides that chemically modify natural DNA / RNA is being actively studied.

[0005] Although excellent modified or artificial nucleic acids have been reported so far, the discovery of side effects caused by binding to non-target nucleic acids having sequences similar to target nucleic acids (off-target effects in a narrow sense) and toxicity unique to nucleic acid drugs that do not depend on target nucleic acid recognition (off-target effects in a broad sense) are issues that should be addressed for practical application, and research on their reduction and improvement is being conducted worldwide.

[0006] As a methodology to overcome the generalized off-target effects, a scheme to reduce the dosage of nucleic acid drugs has been proposed. However, if the dosage is reduced, the amount of complex formed with the target RNA will of course decrease, and effective drug efficacy cannot be expected. Specifically, using ASOs whose intracellular introduction amount is reported to be limited to sub-nM levels, feedback mechanisms have been reported not only in systems targeting mRNAs with sub-μM expression levels, but also in systems targeting miRNAs that function at nM-pM intracellular expression levels, and it is pointed out that drug efficacy strategies based on 1:1 complex formation between target RNA and ASO cannot expect sufficient therapeutic effects.

[0007] As a solution to this problem, nucleic acid drugs with catalyst-like functions that utilize RNaseH and can cleave target RNA as a catalyst using a small amount of ASO have attracted attention (Non-Patent Document 1).

[0008] Prior art documents

[0009] Non-patent literature

[0010] Non-patent literature 1: Liang, X. et al., Mol. Ther. 2017, 25, 2075 Summary of the invention

[0011] The object of the present invention is to provide a chimeric molecule that can inhibit the function of a target nucleic acid at a low concentration and can inhibit off-target effects, a pharmaceutical composition comprising the chimeric molecule, a method for cleaving a target nucleic acid using the chimeric molecule, and a target nucleic acid cleavage or diagnosis kit comprising the chimeric molecule.

[0012] The inventor of the present invention believes that increasing the metabolic renewal rate is effective for improving the efficiency of RNA enzyme cutting target RNA. From this viewpoint, by focusing on the dissociation process after RNA cutting, a design method for an oligonucleotide system that helps to build a complex that can rapidly dissociate from the target RNA after cutting is proposed, and a demonstration experiment is successfully carried out. Discovery utilizes this method, then the function of target nucleic acid can be suppressed at low concentrations, and the effect of missing the target can be suppressed, thereby completing the present invention.

[0013] The present invention includes the following aspects.

[0014] [1] A chimeric molecule comprising a fusion of a first nucleic acid or a derivative thereof having the ability to bind to a target nucleic acid and a second nucleic acid or a derivative thereof having the ability to bind to the target nucleic acid and having an anionic main chain skeleton.

[0015] [2] The chimeric molecule according to [1], wherein the main chain backbone of the first nucleic acid or its derivative is neutral or cationic.

[0016] [3] The chimeric molecule according to [2], wherein the main chain skeleton of the first nucleic acid or its derivative is an amide skeleton.

[0017] [4] The chimeric molecule according to any one of [1] to [3], wherein the main chain backbone of the second nucleic acid or its derivative is a sugar-phosphate backbone.

[0018] [5] The chimeric molecule according to any one of [1] to [4], wherein the first nucleic acid or its derivative is fused to the 5' end of the second nucleic acid or its derivative.

[0019] [6] The chimeric molecule according to any one of [1] to [4], wherein the first nucleic acid or its derivative is fused to the 3' end of the second nucleic acid or its derivative.

[0020] [7] The chimeric molecule according to any one of [1] to [6], wherein a complex consisting of the chimeric molecule and the target nucleic acid bound to the chimeric molecule specifically binds to a nuclease.

[0021] [8] The chimeric molecule according to [7], wherein the nuclease cleaves the target nucleic acid at the fusion portion between the first nucleic acid or its derivative and the second nucleic acid or its derivative.

[0022] [9] The chimeric molecule according to [8], wherein the melting temperature Tm of the two target nucleic acid fragments after cleavage with the nuclease is 38°C or less.

[0023]

[10] The chimeric molecule according to any one of [7] to [9], wherein the nuclease is ribonuclease H.

[0024]

[11] The chimeric molecule according to any one of [1] to

[10] , wherein the first nucleic acid or its derivative is a peptide nucleic acid or a peptide ribonucleic acid or a derivative thereof.

[0025]

[12] The chimeric molecule according to any one of [1] to

[11] , wherein the second nucleic acid or its derivative is DNA.

[0026]

[13] The chimeric molecule according to any one of [1] to

[12] , wherein the target nucleic acid is RNA or DNA.

[0027]

[14] A pharmaceutical composition comprising the chimeric molecule described in any one of [1] to

[13] as an active ingredient.

[0028]

[15] The pharmaceutical composition according to

[14] , wherein the pharmaceutical composition is used for cancer or ischemic brain disease.

[0029]

[16] A method for cleaving a target nucleic acid, comprising cleaving the target nucleic acid using the chimeric molecule described in any one of [1] to

[13] and a nuclease.

[0030]

[17] The method for cleaving a target nucleic acid according to

[16] , wherein the nuclease is ribonuclease H.

[0031]

[18] A kit for target nucleic acid cleavage or diagnosis, comprising the chimeric molecule described in any one of [1] to

[13] and a nuclease.

[0032]

[19] The kit according to

[18] , wherein the nuclease is ribonuclease H.

[0033] According to the present invention, there can be provided a chimeric molecule that can inhibit the function of a target nucleic acid at a low concentration and can inhibit off-target effects, a pharmaceutical composition comprising the chimeric molecule, a method for cleaving a target nucleic acid using the chimeric molecule, and a target nucleic acid cleavage or diagnosis kit comprising the chimeric molecule. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The system was used to mix 10 times the amount of RNA labeled with a fluorescent dye at the 5' end, and the P R Figure 1 shows the cleavage products of PD-RNA complexes produced by RNaseH. Lane 1 shows the ladder and base sequence of RNA1, lane 2 shows the case where 60 U / μL RNaseH is added to the complex of DNA1 and RNA1, lane 3 shows the case where 6 U / μL RNaseH is added to the complex of DNA1 and RNA1, and lane 4 shows the case where 6 U / μL RNaseH is added to the complex of P R When 60 U / μL RNase H was added to the complex of PD1 and RNA1, lane 5 shows R Polyacrylamide gel electrophoresis pattern of RNA1 cleavage products generated by RNaseH when 6 U / μL RNaseH was added to the complex of PD1 and RNA1.

[0035] Figure 2A is a diagram showing the RNA1 cleavage site of RNaseH in the case of a DNA1-RNA1 complex.

[0036] Figure 2B It is shown in P R Diagram of the RNA1 cleavage site of RNaseH in the context of the PD1-RNA1 complex.

[0037] Figure 3 The system uses a mixture of 10 times the amount of RNA labeled with a fluorescent dye at the 5' end and analyzes DNA1, P R PD4, P R Figure 1 shows the cleavage products of the complex of PD1 or PD2 and RNA1 produced by RNaseH. Lanes 1 to 5 show the addition of RNA1 (control), DNA1, P R PD4, P R Polyacrylamide gel electrophoresis patterns of RNA1 cleavage products produced by RNaseH in the case of PD1 and PD2. Lane 6 shows the ladder of RNA1.

[0038] Figure 4The system uses a mixture of 10 times the amount of RNA labeled with a fluorescent dye at the 5' end and analyzes DNA2, P by polyacrylamide gel electrophoresis. R Figure 1 shows the cleavage products of the complex of PD7 or PD1 and RNA2 produced by RNaseH. Lane 1 shows the ladder of RNA2, and lanes 2-5 show the addition of RNA2 (control), DNA2, and P, respectively. R Polyacrylamide gel electrophoresis patterns of RNA2 cleavage products produced by RNaseH in the case of PD7 and PD1.

[0039] Figure 5 The system uses a mixture of 10 times the amount of RNA labeled with a fluorescent dye at the 5' end and analyzes DP by polyacrylamide gel electrophoresis. R P1 or P R Figure 1 shows the cleavage product of the complex of PD5 and RNA1 produced by RNaseH. Lane 1 shows the ladder and nucleotide sequence of RNA1, and lanes 2-8 show the addition of RNA1 (control), PD5 and RNA1, respectively. R PD5(10nM), P R PD5(1nM), P R PD5(0.1nM), DP R P1(10nM),DP R P1 (1 nM) and DP R Polyacrylamide gel electrophoresis pattern of RNA1 cleavage products produced by RNaseH in the presence of P1 (0.1 nM).

[0040] Figure 6 It shows that RNaseH has a R Diagram of the RNA cleavage site of the P1-RNA1 complex.

[0041] Figure 7 In the cell-free translation system, P R The antisense activity of PD2 and DNA2. Lanes 1-3 show the results in the absence of RNaseH, and lanes 4-6 show the results in the presence of RNaseH. Lanes 1 and 4 show the case of adding a control, lanes 2 and 5 show the case of adding DNA2, and lanes 3 and 6 show the case of adding P R PD2 situation.

[0042] Figure 8 In the cell-free translation system, P R PD5 and DP R Lanes 1, 3 and 5 show the results in the absence of RNaseH, and lanes 2, 4 and 6 show the results in the presence of RNaseH. Lanes 1 and 2 show the case of adding a control, and lanes 3 and 4 show the case of adding P RIn the case of PD5, lanes 5 and 6 show the addition of DP R The situation of P2. DETAILED DESCRIPTION

[0043] [Chimeric molecules]

[0044] The chimeric molecule of the present invention is a fusion of a first nucleic acid or a derivative thereof having the ability to bind to a target nucleic acid and a second nucleic acid or a derivative thereof having the ability to bind to the target nucleic acid and having an anionic main chain skeleton.

[0045] In the present invention, there are no particular limitations on the derivatives of nucleic acids, and examples thereof include halogenated derivatives, deamination derivatives, or derivatives having sulfur atoms instead of oxygen atoms of each nucleic acid base whose base portion bound to the nucleic acid is uracil, cytosine, thymine, adenine, guanine, or a purine ring or pyrimidine ring.

[0046] The first nucleic acid or its derivative having binding ability to the target nucleic acid preferably has a neutral or cationic main chain skeleton, more preferably neutral. As the neutral main chain skeleton, there is no particular limitation, and for example, an amide skeleton can be cited. As the nucleic acid or its derivative having an amide skeleton, for example, peptide nucleic acid or its derivative (hereinafter also referred to as Peptide nucleic acid; PNA), peptide ribonucleic acid or its derivative (hereinafter also referred to as PRNA), a combination of PRNA and PNA (hereinafter also referred to as PNA / PRNA), etc. can be cited. In PNA / PRNA, the binding site of PRNA in PNA can be any site of PNA, or it can be bound to the middle of PNA. For example, it can be a combination such as PNA-PRNA-PNA.

[0047] The cationic main chain skeleton is not particularly limited, and examples thereof include an imino skeleton, a phosphoroamide or a phosphoramidite skeleton, etc. Examples of nucleic acids or derivatives thereof having the above skeletons include morpholino nucleic acids, etc.

[0048] The main chain backbone of the second nucleic acid or its derivative having binding ability to the target nucleic acid and an anionic main chain backbone is not particularly limited, but a sugar-phosphate backbone is preferred. As nucleic acids or their derivatives having a sugar-phosphate backbone, for example, ribonucleic acid (Ribonucleic acid; hereinafter also referred to as RNA), deoxyribonucleic acid (Deoxyribonucleic acid; hereinafter also referred to as DNA), etc. can be cited.

[0049] The target nucleic acid is not particularly limited as long as it is a nucleic acid or a derivative thereof having a target sequence to which the chimeric molecule of the present invention can bind, but RNA or DNA is preferred. When the chimeric molecule of the present invention is used as a pharmaceutical composition, the target nucleic acid is preferably RNA or DNA that encodes a protein that causes a disease to be treated with the pharmaceutical composition.

[0050] The first nucleic acid or its derivative may be fused to any one of the 3' end and the 5' end of the second nucleic acid or its derivative.

[0051] Examples of the chimeric molecule in which the first nucleic acid or its derivative is fused with the second nucleic acid or its derivative of the present invention include a fusion product of PNA as the first nucleic acid or its derivative and DNA as the second nucleic acid or its derivative (hereinafter also referred to as a PNA-DNA chimeric molecule), a fusion product of PNA / PRNA as the first nucleic acid or its derivative and DNA as the second nucleic acid or its derivative, etc. Examples of the fusion product of PNA / PRNA as the first nucleic acid or its derivative and DNA as the second nucleic acid or its derivative include a chimeric molecule in which PNA / PRNA is fused to the 5' side of DNA (hereinafter also referred to as a PNA / PRNA-DNA chimeric molecule, ... R Chimeric molecules in which PNA / PRNA is fused to the 3' side of DNA (hereinafter also referred to as DNA-PNA / PRNA chimeric molecules, DP R P) etc.

[0052] The chimeric molecules of the present invention can be prepared as follows.

[0053] A PNA-DNA chimeric molecule in which the first nucleic acid is PNA and the second nucleic acid is DNA can be prepared, for example, as follows.

[0054] (Synthesis of PNA oligomers)

[0055] PNA oligomers can be synthesized by a known solid phase peptide synthesis method. For example, FmocPNA monomers can be protected by a benzoyl group and synthesized by Fmoc-solid phase peptide synthesis (hereinafter also referred to as Fomc-SPPS method) through the following steps.

[0056] [Chemical formula 1]

[0057]

[0058] In the above, a lysine residue is introduced at the N-terminus or C-terminus to improve water solubility and inhibit acyl transfer reaction. The synthesis can be carried out by a known method using NovaSyn (registered trademark) TGR resin or the like. The condensation reaction of the benzoyl-protected Fmoc-PNA monomer can be carried out, for example, by treating it in an NMP (N-methylpyrrolidone) solution containing Fmoc-PNA (Bz)-OH (10 equivalents), HATU (1-[bis(dimethylamino)methyliumyl]-1H-1,2,3-triazolo[4,5-b]pyridine-3-oxidehexafluorophosphate; 10 equivalents), HOAt (1-hydroxy-7-azabenzotriazole; 10 equivalents) and DIEA (N,N-diisopropylethylamine; 20 equivalents) for 30 minutes. The Fmoc group can be removed by treating it with an NMP solution containing 20% ​​piperidine for 20 minutes. These coupling and Fmoc group removal steps are repeated until the target sequence is reached. Deprotection of the benzoyl group can be carried out by treatment with 28% aqueous ammonia at 60°C. Finally, the dissociation and deprotection of the Boc group of the lysine residue are carried out by treatment with a mixture of TFA (trifluoroacetic acid) / TIPS (triisopropylsilane) / phenol / water (94:3:1:2). The obtained crude product can be purified by reverse phase HPLC, and the purified product can be identified by ESI-TOF-MS.

[0059] (Synthesis of PNA-DNA Chimeric Molecules)

[0060] PNA-DNA chimeric molecules can be synthesized, for example, as follows, by applying a benzoyl-protected Fmoc monomer synthesized by a known method to a target sequence.

[0061] [Chemical formula 2]

[0062]

[0063] The N-terminus of the PNA molecule is modified with glycine to inhibit the acyl transfer reaction. DNA is synthesized starting from the construction of the DNA molecule by a DNA / RNA automatic synthesizer using a CPG resin bound to an adenine residue.

[0064] DNA molecules can be extended by the usual phosphoramidite method using 5-BMT as an activator. Using 5'-MMTr (monomethoxytrityl) aminodeoxynucleotide phosphoramidite prepared by a known method, a 5'-amino-modified deoxynucleotide derivative is introduced into the 5' end of the DNA molecule. After the 5'amino-modified derivative is introduced by a DNA synthesizer, the MMTr group at the 5' end of the DNA is removed by treating it with a 3% TCA / DCM solution for 15 minutes. Next, in order to bond PNA via an amide bond, the 5' amino group of the DNA is used and extended by the Fmoc-SPPS method.

[0065] The condensation reaction of FmocPNA using benzoyl protection was carried out in an NMP solution containing Fmoc-PNA (Bz) -OH (10 equivalents), HATU (10 equivalents), HOAt (10 equivalents) and DIEA (20 equivalents) for 30 minutes. The acetyl end-capping of unreacted amino groups on the resin can be carried out under 25% acetic anhydride / DCM. The Fmoc group can be removed by 20% piperidine / NMP treatment. Repeat these coupling, acetyl end-capping and Fmoc removal steps until the target sequence is obtained. Finally, the dissociation and deprotection of the cyanoethyl group of the benzoyl group and the DNA molecule are carried out by treating with 28% ammonia for 60 minutes. The resulting crude product can be purified by reverse phase HPLC, and the purified product can be identified by MALDI-TOF-MS.

[0066] (PNA / PRNA-DNA chimeric molecule; P R Synthesis of PD)

[0067] PNA / PRNA fused to the 5' side of DNA R The synthesis of PD can be carried out by the same method as the synthesis of the PNA-DNA chimera molecule, for example, by the following steps.

[0068] [Chemical formula 3]

[0069]

[0070] The PRNA monomer can be introduced into a specific site of the PNA molecule based on the Fmoc-SPPS method. The PRNA monomer (Fmoc-γPRNA-OH) can be prepared, for example, by the following steps.

[0071] [Chemical formula 4]

[0072]

[0073] The crude product was purified by reverse phase HPLC and the purified product was identified by MALDI-TOF-MS.

[0074] (DNA-PNA / PRNA chimeric molecule; DPR Synthesis of P

[0075] DP fused to the 3' end of DNA R The synthesis of P can be performed by, for example, the Fmoc-SPPS method using a DNA synthesizer through the following steps.

[0076] [Chemical formula 5]

[0077]

[0078] The synthesis was started by introducing Fmoc-Gly-OH onto NovaSyn (registered trademark) TGA resin using a condensation reagent of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl) and 4-dimethylaminopyridine in DMF (N,N-dimethylformamide).

[0079] The synthesis is preferably carried out using Fmoc-Gly functional TGA resin by Fmoc-SPPS method. PNA / PRNA molecules can be synthesized by Fmoc-SPPS method using benzoyl protection Fmoc-PNA and Fmoc-γPRNA monomer extension. The coupling conditions can be the same as those of PNA-DNA chimeric molecules. After Fmoc-SPPS is completed, the 2',3'-hydroxyl groups of the PRNA molecules are protected with acetyl groups. After removing the Fmoc group at the N-terminus, the resin is used with a DNA synthesizer to extend the DNA molecule from the N-terminal amino group of the PNA / PRNA molecule bound by a phosphoramidite bond by the well-known phosphoramidite method. Finally, dissociation and deprotection are carried out with 28% ammonia. The crude product obtained can be purified by reverse phase HPLC, and the purified product can be identified by MALDI-TOF-MS.

[0080] (Effect on nuclease)

[0081] The complex formed by the chimeric molecule of the present invention and the target nucleic acid bound to the chimeric molecule specifically binds to a nuclease. As the nuclease, ribonuclease H is preferably used, but not limited thereto, and the type of ribonuclease is not particularly limited as long as it specifically binds to the complex.

[0082] The nuclease has a site for recognizing the second nucleic acid or its derivative (hereinafter also referred to as nucleic acid recognition site) and a nuclease active site for cutting the target nucleic acid. The nucleic acid recognition site of the nuclease has a channel structure consisting of basic amino acid residues, thereby binding to the second nucleic acid or its derivative having an anionic backbone. When the second nucleic acid or its derivative is combined with the nucleic acid recognition site, the first nucleic acid or its derivative fused with the second nucleic acid or its derivative is attracted to the cutting active site of the nuclease, thereby selectively cutting the target nucleic acid at the fusion (joining) site of the first nucleic acid or its derivative and the second nucleic acid or its derivative.

[0083] The chimeric molecule of the present invention is capable of cleaving the target sequence bound to the chimeric molecule of the present invention at the fusion (joining) site between the first nucleic acid or its derivative and the second nucleic acid or its derivative, and thus by designing a chimeric molecule having the fusion site as the cleavage site of the target nucleic acid, the target nucleic acid can be cleaved at the target site.

[0084] In the chimeric molecule of the present invention, the melting temperature (Tm) of the two target nucleic acid fragments after cutting with the nuclease is preferably below body temperature, for example, it can be below 38°C, or below 37°C, below 30°C, or below 25°C. By making the Tm of the two target nucleic acid fragments below body temperature, the two target nucleic acid fragments produced by the cutting of the nuclease at one position can be rapidly dissociated from the nuclease. On the other hand, after the nuclease cuts the target nucleic acid, the chimeric molecule of the present invention quickly dissociates from the nuclease, so the chimeric molecule of the present invention is quickly used for the next target nucleic acid cutting, and the efficient renewal of the target nucleic acid cutting by the nuclease can be achieved. Therefore, the chimeric molecule of the present invention can cut the target nucleic acid at a low concentration, thereby reducing the off-target effect.

[0085] [Drug composition]

[0086] The pharmaceutical composition of the present invention contains the chimeric molecule of the present invention as an active ingredient.

[0087] In the present invention, the pharmaceutical composition is not particularly limited, and examples thereof include pharmaceutical compositions for treating diseases caused by proteins encoded by target nucleic acids targeted by the chimeric molecules of the present invention, such as anti-tumor agents, ischemic brain disease therapeutic agents, etc. The pharmaceutical composition of the present invention can cleave the target nucleic acid by endogenous nucleases, inhibit the expression of proteins encoded by the target nucleic acid, and thus can treat diseases caused by proteins encoded by the target nucleic acid.

[0088] In principle, any protein can be encoded by the target nucleic acid as long as it is a protein that is a target of the pharmaceutical composition of the present invention. For example, examples of proteins that are targets of the pharmaceutical composition of the present invention include TGFβ, which is a therapeutic target for idiopathic pulmonary fibrosis, mutant p53 and activated ras, which are therapeutic targets for cancer, and VEGF165, which is a therapeutic target for age-related macular degeneration.

[0089] The disease is not particularly limited, and examples thereof include cancer, ischemic encephalopathy, age-related macular degeneration, familial hypercholesterolemia, muscular dystrophy, dementia, NASH, cirrhosis, idiopathic pulmonary fibrosis, liver disease, autoimmune disease, kidney disease, hematopoietic system disease, atopic dermatosis, psoriasis, and the like.

[0090] The pharmaceutical composition of the present invention may be in various forms, such as liquid (e.g., injection), dispersion, suspension, tablet, pill, powder, suppository, etc. The preferred embodiment is injection, preferably non-oral (e.g., intravenous, transdermal, intraperitoneal, intramuscular) administration.

[0091] As the pharmaceutical composition of the present invention, it can be used not only as a single dose according to the above-mentioned dosage form, but also can be selected with a mixture of nucleic acid drugs or low molecular weight drugs, antibody drugs, etc. of different compositions, and the dosage form or delivery system used during administration is the most suitable dosage form or delivery system. In addition, various methods of administration such as the form in which the pharmaceutical composition of the present invention is directly or modified and enclosed in micelles or combined with antibody drugs, etc. can be selected. The pharmaceutical composition of the present invention is different according to the type of disease or the type of target nucleic acid, for example, it can be 0.025-50 mg / kg, preferably 0.1-50 mg / kg, more preferably 0.1-25 mg / kg, further preferably 0.1-10 mg / kg or 0.1-3 mg / kg, but is not limited thereto.

[0092] [Target Nucleic Acid Cleavage Method and Target Nucleic Acid Cleavage or Diagnosis Kit]

[0093] The target nucleic acid cleavage method of the present invention uses the chimeric molecule and nuclease of the present invention. As the nuclease, the above-mentioned nuclease can be cited. By the target nucleic acid cleavage method of the present invention, the target sequence can be specifically cleaved, and therefore, in addition to sequence selective cleavage of the target nucleic acid and genome editing tools, the method can also be used to diagnose diseases caused by proteins encoded by the target nucleic acid.

[0094] The target nucleic acid cutting or diagnostic kit of the present invention comprises the chimeric molecule of the present invention and a nuclease. As nucleases, the above-mentioned nucleases can be cited. In the target nucleic acid cutting kit of the present invention, in addition to the chimeric molecule and nuclease of the present invention, other components required for the detection of target nucleic acid fragments, such as acrylamide gel, reaction buffer, reaction container, etc., can also be included. The target nucleic acid cutting kit of the present invention can specifically cut the target nucleic acid, so it can be used as a sequence-selective cutting target nucleic acid and genome editing tool. In addition, the diagnostic kit of the present invention can be used to diagnose diseases caused by proteins encoded by the target nucleic acid targeted by the chimeric molecule of the present invention. As proteins encoded by the target nucleic acid targeted by the chimeric molecule of the present invention, the above-mentioned proteins can be cited.

[0095] The diagnostic kit of the present invention can determine whether the biological sample of the subject contains the target nucleic acid by detecting, for example, whether the nucleic acid in the biological sample of the subject can be cleaved by the diagnostic kit of the present invention, and thus can diagnose whether the subject suffers from a disease caused by the protein encoded by the target nucleic acid targeted by the chimeric molecule of the present invention. The biological sample is not particularly limited, and examples thereof include blood, saliva, urine, cerebrospinal fluid, bone marrow fluid, pleural effusion, ascites, joint fluid, tears, vitreous humor, vitreous humor, and lymph fluid.

[0096] In addition, by introducing the constituent elements of the diagnostic kit of the present invention into the body, it can also be used to detect in vitro structural changes or physicochemical changes in the detection probe molecules caused by the in vivo environment or the presence or absence, concentration, etc. of the target molecule, and to perform in vitro diagnosis by highly sensitively measuring the energy changes caused by externally detecting light or magnetism, ultrasound, radiation, etc. irradiated or exposed from outside the body, and visualized as an image.

[0097] Example

[0098] Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to the following Examples.

[0099] [Example 1] Preparation of PNA-DNA chimeric molecules

[0100] PNA-DNA chimeric molecules were synthesized by automated DNA synthesis and Fmoc-SPPS method using CPG resin.

[0101] The synthesis starts from the construction of the DNA molecule by an automatic DNA synthesizer. In order to synthesize CPG resin DNA carrying 2'-deoxyadenosine residues, CPG resin (1 μM level) bound to adenine residues is introduced into the DNA synthesizer, and the DNA molecule is used as an activator and extended by the usual phosphoramidite method using 5-BMT. The concentration of the phosphoramidite solution is 70-78mM in acetonitrile. Using 5'-MMTrNH deoxycytidine phosphoramidite prepared according to a known method, 5'-amino modified deoxycytidine derivatives are introduced into the 5' end of the DNA molecule. Using the final trityl "ON" process, after the 5'-amino modified derivative is introduced into the DNA synthesizer, the resin is removed from the DNA synthesizer and transferred to the reaction column for the Fmoc-SPPS process. The MMTr group at the 5' end of the DNA is removed by treating with a 3% TCA / DCM solution for 15 minutes.

[0102] Then, using the 5'amino group of DNA as the basis of the amide bond, PNA was extended by the Fmoc-SPPS method. In order to make the amino groups on the surface alkaline, the resin was treated with 20% piperidine / NMP, filtered, and washed with NMP more than 5 times. The condensation reaction of the FmocPNA monomer using benzoyl protection was carried out by treating with an NMP solution (300 μL) containing Fmoc-PNA (Bz) -OH (10 equivalents), HATU (10 equivalents), HOAt (10 equivalents) and DIEA (20 equivalents). The reaction was carried out at room temperature for 30 minutes while stirring vigorously from time to time, and then the solution was removed and the resin was washed with NMP more than 3 times.

[0103] Then, add 20% piperidine solution in NMP to the resin and stir occasionally for 20 minutes to remove the Fmoc group. After the Fmoc group is removed, wash the resin with NMP for more than 5 times. Repeat the condensation reaction and Fmoc removal process until the sequence of the target PNA-DNA chimeric molecule is constructed.

[0104] Finally, Fmoc-Gly-OH was introduced under the same condensation conditions as above to inhibit the transfer of the molecular acyl group within the N-terminal amino group of the PNA residue. After the Fmoc-SPPS process was completed, all protective groups were removed by treating the resin in a 28% ammonia solution at 60°C for 16 hours and separating it from the resin. The resin was then removed by filtration and the filtrate was concentrated. 18 -AR-II column (nacalai, 10Φ×250 mm), at a flow rate of 3 mL / min, using solvent A: 0.1 M TEAA buffer (pH 7.5), solvent B: 0.1 M TEAA (pH 7.5) / acetonitrile (1:1, v / v) in a linear gradient from 5% to 70% in 30 minutes, and the crude product was purified by reverse phase HPLC.

[0105] The two types of PNA-DNA chimeric molecules (PD1 and PD2) shown in the following Table 1 were prepared by the above method.

[0106] [Table 1]

[0107]

[0108] Lowercase letters represent PNA bases, uppercase letters represent DNA bases, HN T. HN C represents a 5'-amino substituted DNA base.

[0109] [Example 2] R Preparation of PDs

[0110] As a DNA-PNA / PRNA chimeric P in which PNA / PRNA is fused to the 5' end of DNA R PD was synthesized by a combination of an Fmoc process using a DNA automatic synthesizer and a CPG resin.

[0111] The synthesis starts with the construction of the DNA molecule by automatic DNA synthesis. A CPG resin (1 μM level) loaded with 2' deoxynucleoside residues is introduced into a DNA synthesizer, and the length of the DNA molecule is extended by the usual phosphoramidite method using 5-BMT as an activator. The concentration of the phosphoramidite solution is 70-78 mM in acetonitrile. Using 5'-MMTrNH deoxycytidine phosphoramidite prepared according to a known method, a 5' amino-modified deoxynucleotide derivative is introduced into the 5' end of the DNA molecule.

[0112] After the 5'-amino modified derivative was introduced by DNA synthesizer using the final trityl "ON" step, the resin was removed from the DNA synthesizer and transferred to the reaction column for Fmoc-SPPS step. The MMTr group at the 5' end of the DNA was removed by treating with 3% TCA / DCM solution for 15 minutes.

[0113] Then, PNA was extended by Fmoc-SPPS method using the 5' amino group of DNA as the base of amide bond. In order to make the amino group on the surface basic, the resin was treated with 20% piperidine / NMP, filtered, and washed with NMP for more than 5 times.

[0114] The condensation reaction of the FmocPNA monomer protected by benzoyl was carried out by treatment with a NMP solution (300 μL) containing Fmoc-PNA(Bz)-OH (10 equivalents), HATU (10 equivalents), HOAt (10 equivalents) and DIEA (20 equivalents). The reaction was carried out at room temperature for 30 minutes with occasional strong stirring, and then the solution was removed and the resin was washed with NMP three more times.

[0115] Then, a 20% piperidine solution in NMP is added to the resin and stirred from time to time for 20 minutes to remove the Fmoc group. After the Fmoc group is removed, the resin is washed with NMP for more than 5 times. The condensation reaction and Fmoc removal process are repeated until the target PNA-DNA chimeric sequence is constructed. Finally, Fmoc-Gly-OH or Fmoc-Lys(Fmoc)-OH is introduced under the same condensation conditions as above to inhibit the molecular acyl transfer within the N-terminal amino group of the PNA residue.

[0116] After the Fmoc-SPPS process was completed, all protecting groups were removed by treating the resin in 28% ammonia solution at 60°C for 16 hours and then separating from the resin.

[0117] Then, the resin was removed by filtration and the filtrate was concentrated. 18 -AR-II column (nacalai, 10Φ×250 mm), at a flow rate of 3 mL / min, using solvent A: 0.1 M TEAA buffer (pH 7.5), solvent B: 0.1 M TEAA (pH 7.5) / acetonitrile (1:1, v / v) in a linear gradient from 5% to 70% in 30 minutes, and the crude product was purified by reverse phase HPLC.

[0118] The 7 kinds of P shown in Table 2 were prepared by the above method. R PD(P R PD1~P R PD7).

[0119] [Table 2]

[0120]

[0121] Italic letters represent PRNA bases, lowercase letters represent PNA bases, and uppercase letters represent DNA bases. HN T. HN C represents a 5'-amino substituted DNA base.

[0122] [Example 3] DP R Preparation of P

[0123] Fmoc-Gly-OH (30 mg, 100 μmol) and EDC·HCl (19 mg, 100 μmol) were dissolved in DMF (1.0 mL), and the solution was stirred for 35 minutes under ice cooling. The ice cooling was removed, and NovaSyn (registered trademark) TGA resin (42 mg, 10 μmol of hydroxyl groups) in DMF and DMAP (1.2 mg, 10 μmol) was added to the solution, and the resulting mixture was stirred at room temperature for 1.5 hours. The resin was filtered and washed with NMP, DCM / ethanol (1:1, v / v) and DCM successively.

[0124] After fully washing the resin, 1.0 mL of benzoic anhydride (113 mg, 0.5 mmol) of 20% pyridine / NMP solution was added to the resin, and the mixture was placed at room temperature while shaking from time to time. After being placed for 1 hour, the resin was fully washed with NMP and DCM. After washing with ethanol, the resin was dried in a desiccator under reduced pressure to obtain Fmoc-Gly functional TGA resin (41 mg, 94%). The amount of Fmoc-Gly-OH introduced was calculated by quantitative UV (301 nm) measurement of the free Fmoc-Gly-OH treated with 20% piperidine / NMP.

[0125] The Fmoc-Gly functional TGA resin (1 μmol level) obtained as above was washed with NMP and treated with 20% piperidine / NMP for 20 minutes at room temperature to remove the Fmoc protecting group. After being fully washed with NMP, the resin was added to an NMP solution (300 μL) of Fmoc-PNA(Bz)-OH or Fmoc-γPRNA-OH (10 equivalents), HOAt (10 equivalents), HATU (10 equivalents) and DIEA (20 equivalents), and the mixture was shaken from time to time while standing at room temperature for 30 minutes, and the coupling process was repeated twice. After washing with NMP and DCM, the resin was treated with 25% acetic anhydride / DCM for 10 minutes at room temperature. After the above coupling process, the resin was washed with DCM and washed with NMP. Then, Fmoc was removed by treating with 20% piperidine / NMP for 20 minutes at room temperature. The PNA-PRNA chain was extended using the same Fmoc removal, coupling and end-capping process. After the last coupling step, the resin was washed thoroughly with NMP and DCM and washed with pyridine. Then, acetic anhydride / DCM (2:3, v / v) was added to the resin and allowed to stand at room temperature for 2 hours while shaking occasionally to protect the 2'3' hydroxyl groups of the pRNA molecules.

[0126] After the N-terminal Fmoc protecting group was removed, the resin was transferred to an empty column for an automatic DNA / RNA synthesizer, and the column containing the resin was installed on the DNA / RNA synthesizer. The DNA chain was extended by the usual phosphoramidite method using a 5'-O-DMTr-3'-O-(2-cyanoethyl)phosphoramidite building block (Building Block). After the chain assembly, the resin was treated with 28% ammonia water at 60°C for 18 hours to make the DP R P was deprotected and dissociated. The resin was then removed by filtration through a membrane filter. The filtrate was partially concentrated under vacuum and analyzed by reverse phase HPLC at 5°C 18 -AR-II column (10×250 mm) to obtain DP R P.

[0127] By the above method, two DPs shown in Table 3 were prepared. R P(DP R P1, DP R P2).

[0128] [Table 3]

[0129]

[0130] Italic letters represent PRNA bases, lowercase letters represent PNA bases, and uppercase letters represent DNA bases. HN T. HN C represents a 5'-amino substituted DNA base.

[0131] [Example 4] Determination of RNase activity

[0132] The following study investigated the cleavage of P by RNase R RNA cleavage activity of PD·RNA complexes.

[0133] The target 5'-FAM labeled RNA (5'-FAM-GAAUCUUAUAGUCUUGCA-3'; RNA1) having the base sequence shown in SEQ ID NO: 12 was mixed with the P obtained in Example 2. R The mixture was annealed to form P R PD-RNA complex.

[0134] Then, 60 U / μL RNaseH was added to the mixture and reacted at 37°C to cleave RNA1. After reacting for 30 minutes, 7 M uric acid Tris-HCl buffer was added to stop the reaction, and then RNaseH was inactivated at 70°C for 10 minutes. RAs a control for PD1, DNA1 (5'-TGCAAGACTATAAGATTC-3') having the base sequence shown in sequence number 13 of the paired portion was subjected to the same treatment. The RNA fragments after cutting were analyzed by 20% resolved polyacrylamide gel electrophoresis (resolved PAGE), visualization and quantification using a fluorescent image analyzer. The results are shown in Figure 1 and Table 4.

[0135] [Table 4]

[0136]

[0137] like Figure 1 As shown in Table 4, when 60 U / μL RNase H was used for DNA1, 54% of RNA1 was cleaved. R In the case of PD1, more than 99% of RNA1 was cleaved, which means that the activity of RNaseH was saturated. Therefore, the amount of RNaseH was reduced to 6U / μL and the cleavage experiment of the same RNA was performed.

[0138] The results are as follows Figure 1 As shown in Table 4, the degree of RNA1 cleavage was reduced to 12% in the case of DNA1, while P R The cleavage of RNA1 was maintained at more than 90% in the case of PD1. R The PD1·RNA1 complex showed 8-fold higher RNA1 cleavage activity.

[0139] P R The cleavage site of PD1 is Figure 2B As shown, it is a site near the PNA-DNA amide bond. In contrast, in the case of DNA1, Figure 2A As shown, it is cut at multiple sites. The minimum DNA base length for RNaseH to bind is 5-6 bases, which corresponds to the distance between the DNA binding channels of RNaseH. Therefore, P R The DNA molecule of PD1 consists of 7 DNA nucleic acid bases, which can be correctly recognized by the DNA binding channel of RNaseH introduced into a cleavage site. DNA-RNA complexes using 5-6 base pairs can be connected at several sites. This induces RNA cleavage at multiple sites. Based on these, the promotion of RNA cleavage is explained as follows.

[0140] RNaseH does not have base sequence selectivity for target RNA, so in the case of DNA1, the cleavage sites of the complex with the target RNA are various, and it is highly likely that one cleavage will not cause the complex to dissociate, and the cleavage RNA cannot be dissociated from the ASO-cleavage RNA-RNaseH complex, and the number of DNA1 renewals decreases. On the other hand, it is believed that in the P as the chimeric molecule of the present invention, R In the case of PD1, it is possible to achieve cleavage at one site of the target RNA, especially before and after the sequence where the stability of the complex after cleavage is below body temperature (37°C). Through one cleavage, the complex can be efficiently dissociated and combined with other uncut target RNAs, thereby dramatically increasing the number of renewals. This was confirmed by calculating the Tm of the complex of the two fragments after cleavage of the RNA1·DNA1 complex after cleavage and the ASO using the nearest base method using actual measurements or thermodynamic parameters.

[0141] like Figure 2A As shown, in the case of DNA1, cleavage was non-specifically observed at different sites (a to e). The stability of the complex after cleavage was calculated. In the cleavage at site a and site d, the complex after cleavage with DNA1 was Tm = 35.3°C and 37.2°C, respectively. This is roughly the same as body temperature (37°C), and it can be expected that the complex is difficult to dissociate even after cleavage. Even if cleavage is performed at other sites, the Tm of the complex with the cleavage fragment is mostly above 37°C. Although the Tm of the complex between the RNA fragment and DNA1 after cleavage of some cleavage fragments (sites b and c) is below 37°C, the probability of its generation is not high. Therefore, multiple RNaseH cleavages are usually required for complex dissociation, resulting in the inhibition of the renewal number of RNaseH cleavages.

[0142] In contrast, P R PD1 showed selective one RNA cleavage at the PNA-DNA junction, which greatly reduced RNA1·P compared with the RNA before cleavage. R The temperature stability of the PD1 complex. Therefore, after one RNaseH cleavage, the complex dissociates and the ASO is able to form a complex with the target RNA that is not immediately cleaved. As a result, the number of RNaseH cleavage turnovers is promoted. In this experiment, all RNA1 was cleaved. To confirm this, the RNA-P R Tm of PD1 complex.

[0143] like Figure 2B As shown, the main cleavage site is one of the sites a. Thus, the generated fragments form a R Different types of complexes of PD1, such as P RThe complex of PD1 and DNA molecule (RNA·DNA complex after cleavage), P R Complex of PD1 and PNA / PRNA molecule (RNA·PNA / PRNA complex after cleavage). The temperature stability of the RNA·DNA complex after cleavage was calculated by the nearest neighbor dynamic parameter, and the result was Tm=13.2°C. The temperature stability of the RNA·PNA / PRNA complex after cleavage was Tm=22.3°C by UV temperature melting analysis. It is reported that PNA forms an unstable complex with DNA / RNA under physiological high salt concentration conditions. Therefore, it is believed that this low temperature stability of the RNA·PNA / PRNA complex after cleavage is reasonable.

[0144] From the above, it can be seen that the cleavage of RNA1 at a selective site in the PNA-DNA fusion region generates an RNA fragment with temperature stability below body temperature (37°C), which is identified as P R Effective update of PD1.

[0145] Next, the effect of the introduction of PRNA into the chimera on RNaseH activity was studied. R PD4, P R In the presence of PD1 or PD2 (10 nM), RNA1 (1 μM) and RNaseH (0.6 U / μL) were reacted at 37°C for 30 minutes. The results are shown in Figure 3 and Table 5.

[0146] [Table 5]

[0147]

[0148] In the case of DNA1, the amount of RNA1 cleavage was very small. In contrast, at 10 nM P R PD4 and P R In the presence of PD1, more than 90% cleavage of RNA1 was observed. R PD4 and P R Compared with PD1, it also showed the same level of RNaseH activity.

[0149] The effect of PRNA introduced into the chimera on RNaseH activity was studied using 16merRNA using RNA2 (5'-FAM-UAAGAAGGAGAUAUAC-3') having the base sequence shown in SEQ ID NO: 14. In the case of DNA2 (5'-GTATATCTCCTTCTTA-3') having the base sequence shown in SEQ ID NO: 15, P RIn the presence of PD7 or PD1 (10 nM), RNA2 (1 μM) and RNaseH (6×10-3 U / μL) were reacted at 37°C for 30 minutes. The results are shown in Figure 4 and Table 6.

[0150] [Table 6]

[0151]

[0152] In the case of DNA2, 52% of RNA2 was cleaved. R In the presence of PD7, 76% RNA2 cleavage was observed, and its RNaseH activity was 1.5 times that of DNA2. In contrast, in the case of PD1, RNA2 cleavage was 40%, which was 2.5 times higher than that of DNA2. R The results showed that the introduction of PRNA into the chimeric molecule promoted RNaseH activity, which was considered to be due to the RNA-selective binding property of the target RNA to form an A-type complex.

[0153] Then, the study was conducted through DP R The RNaseH of P1 cleaves the target RNA1 and interacts with P R The activity of PD5 was compared. R P induces RNA cleavage at the 3' end. RNA1 was mixed with 1 / 100, 1 / 1000 or 1 / 10000 equivalent of DP R P1 or P R PD5 were mixed and annealed separately to form a complex. Then, 6×10 -3 U / μL RNase H was reacted at 37°C for 30 minutes. The results are shown in Figure 5 and Table 7.

[0154] [Table 7]

[0155]

[0156] like Figure 5 As shown, DP R The P1 RNA is cleaved at a site 3-4 bases from the 3' end of the RNA. The main cleavage sites are Figure 6 10nM DP R The cleavage activity of P1 was 43%, which was higher than that of P R The cleavage activity of PD5 was 1.7-fold lower (73%). R This low cleavage activity of P1 is believed to be due to the restrictive RNA1 cleavage site. RIn the case of PD5, the cleavage site is a point at the PNA-DNA junction. Therefore, by generating RNA1 with low temperature stability below 37°C, efficient dissociation of RNA1 and P R Effective update for PD5.

[0157] In contrast, in DP R In the case of P1, cleavage was observed near the 3' end of RNA1, thus generating a long RNA fragment after cleavage that maintained a high temperature stability above 37°C. R The update efficiency of P1 is similar to that of P R PD5 was lower than that of controls.

[0158] [Example 5] Kinetic parameters of RNA cleavage reaction of RNaseH

[0159] To study P R Efficient RNA cleavage by PD5, and kinetic analysis of RNA cleavage by RNaseH.

[0160] In excess P R In the presence of PD1·RNA1 (1, 2, 5, 10 μM), RNaseH (1.5×10 -3 U / μL=4.1nM) were reacted under pseudo-first-order reaction conditions and plotted on each P R Time curve of the amount of RNA1 cleaved at different PD1·RNA1 concentrations. Lineweaver-Burk plot was performed using the initial velocity obtained for each substrate concentration. R The same experiment was performed on P1·RNA1. The kinetic parameters obtained from the Lineweaver-Burk plot are summarized in Table 8. The parameters of the DNA·RNA complex were extracted with reference to the results reported by Otsuka et al. The results are shown in Table 8.

[0161] [Table 8]

[0162]

[0163] As shown in Table 8, P R k of RNA cleavage reaction between PD1·RNA1 complex and RNaseH cat The value is about 1.9 times that of the DNA·RNA complex. This result shows that RNaseH has a higher P value than the corresponding DNA·RNA complex. R The cleavage efficiency of PD1·RNA1 complex was slightly improved, but Figure 3 Compared with the target RNA cleavage experiment shown in Figure 2, the increase rate is significantly lower. RNaseH shows the same RThe high cleavage activity of PD1·RNA1 complex, RNaseH and P R The Michaelis-Menten multiplier (Km) of the binding of the PD1·RNA1 complex is larger than that of the DNA·RNA complex. R The binding activity of PD1·RNA1 complex to RNaseH is lower than that of DNA·RNA complex. cat The relationship between the Km value and the RNaseH recognition rate is R The high RNA cleavage activity of PD1 had little effect. R The Vmax value of the PD1·RNA1 complex is 4 times greater than that of the DNA·RNA complex, but this value is smaller than the value estimated by gel electrophoresis (e.g., based on Figure 1 , an approximately 8-fold higher RNA cleavage activity was observed (comparison of lanes 2 and 4). These results indicate that RNaseH binds to the substrate (P R The binding of PD1-RNA1 complex is not the rate-determining step. R The process of dissociation of the PD1-RNA1 complex from RNaseH is important for the efficient RNA cleavage activity of RNaseH.

[0164] In DP R In the case of P1, the cleavage activity of RNaseH on RNA is k cat The value is smaller than that of DNA·RNA complex. This result shows that DP R P1 showed lower cleavage activity than the corresponding DNA. The Vmax value of RNA cleavage was more than 1.7 times that of the DNA·RNA complex, and the Km value was more than 5.2 times that of the DNA·RNA complex.

[0165] The high Km value compared to the DNA·RNA complex is believed to be due to the reduced recognition of RNaseH caused by the replacement of the natural DNA backbone with the PNA-PRNA backbone. R The Km value of the P1·RNA1 complex is lower than that of the P R PD1-RNA1, which indicates that R Compared with the PD1·RNA1 complex, DP R The RNaseH recognition of the P1·RNA1 complex is enhanced. R P1·RNA1 and P R The difference in Km values ​​between PD1 and RNA1 supports the DP pathway through RNaseH. R The recognition site of the P1·RNA1 complex is different from that of P R Recognition site of the PD1-RNA1 complex.

[0166] Figure 5 The cleavage reactions shown also support that the recognition sites are different. R PD and DP R The different RNaseH activities between P are believed to depend not only on the RNA cleavage site, but also on the recognition and catalytic cleavage activity of RNaseH (k cat / Km). cat The Km value can be determined by the substrate concentration of the kinetic analysis of the RNA cleavage reaction by RNaseH. R PD and DP R P's k cat / Km values ​​are almost of the same order of magnitude (P R PD·RNA:1.67×10 6 s -1 M -1 , DP R P·RNA:1.97×10 6 s -1 M -1 ). It can be considered that the renewal efficiency of chimeric molecules is mainly controlled by the RNA cleavage site. It can be seen that the cleavage site of RNaseH is important for promoting RNA cleavage activity and chimeric renewal efficiency.

[0167] [Example 6] Antisense activity in a cell-free translation system

[0168] To confirm the application of endogenous RNA cleavage, an in vitro cell-free translation system was used to study the P R Protein synthesis inhibitory activity (antisense activity) of PD. R PD2 and DNA2 are 16mers containing 5'-GAAGGA-3', which is the complementary sequence of the Shine-Dalgarno (SD) sequence upstream of the Renilla luciferase gene used in the luciferase reporter assay. 1 / 10 equivalent of ASO (P R PD2 or DNA2). The reaction was carried out in the presence and absence of RNaseH to evaluate the RNA cleavage activity of RNaseH. The results are shown in Figure 7 .

[0169] like Figure 7 As shown in Figure 2, in the absence of RNaseH, almost no antisense activity was observed in the case of DNA2. By adding RNaseH, a slight inhibitory activity of DNA2 was observed (12%). In contrast, in the case of P R In the case of PD2, in the absence of RNaseH, 9% antisense activity was observed, which was slightly higher than that of DNA2.R The antisense activity of PD2 was significantly increased to 91% by the addition of RNaseH. The lower than stoichiometric inhibition level in the absence of RNaseH indicates that the inhibition is caused only by 1:1 complex formation. R In the case of PD2, more than 10% suppression of protein expression was observed. R PD2 plays a catalytic role through RNaseH activity. R PD can effectively cleave target mRNA and inhibit protein production using RNaseH activity. This result is consistent with gel electrophoresis analysis of RNA fragments. Therefore, it is believed that studying the cleavage site of RNA is very important for designing more effective ASOs for antisense activity.

[0170] Then, PURESYSTEM Classic II was used to study the expression of P in the cell-free translation system. R PD5 and DP R The antisense activity of P2 was tested in the absence and presence of RNaseH. The results are shown in Figure 8 .

[0171] Relative to the target mRNA encoding Renilla luciferase gene, 1 / 10 equivalent of P was added R PD5 and DP R P2. In P R In the case of PD5, the antisense activity was increased to 75% by the addition of RNaseH. R P2 promoted antisense activity by adding RNaseH to 12%, compared with P R PD5 is 6 times lower.

[0172] Industrial Applicability

[0173] According to the present invention, there can be provided a chimeric molecule that can inhibit the function of a target nucleic acid at a low concentration and can inhibit off-target effects, a pharmaceutical composition comprising the chimeric molecule, a method for cleaving a target nucleic acid using the chimeric molecule, and a target nucleic acid cleavage or diagnosis kit comprising the chimeric molecule. SEQUENCE LISTING <110> National University Corporation Tohoku University <120> Chimeric molecule, pharmaceutical composition, target nucleic acid cleavage method, and target nucleic acid cleavage or diagnosis kit <130> P73383SIP <140> JP 2019-136414 <141> 2019-07-24 <160> 15 <170> PatentIn version 3.5 <210> 1 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> PNA-DNA chimera <220> <221> misc_feature <222> (1)..(8) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (9)..(9) <223> 5'-amino-substituted DNA <400> 1 gtatatctcc ttctta 16 <210> 2 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> PNA-DNA chimera <220> <221> misc_feature <222> (1)..(10) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (11)..(11) <223> 5'-amino-substituted DNA <400> 2 tgcaagacta taagattc 18 <210> 3 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> PRNA-PNA-DNA chimera <220> <221> misc_feature <222> (1)..(8) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (9)..(9) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (11)..(11) <223> 5'-amino-substituted DNA <400> 3 tgcaagacua taagattc 18 <210> 4 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> PRNA-PNA-DNA chimera <220> <221> misc_feature <222> (1)..(3) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (4)..(4) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (5)..(10) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (11)..(11) <223> 5'-amino-substituted DNA <400> 4 gtauatctcc ttctta 16 <210> 5 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> PRNA-PNA-DNA chimera <220> <221> misc_feature <222> (1)..(3) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (4)..(4) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (5)..(7) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (8)..(8) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (9)..(10) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (11)..(11) <223> 5'-amino-substituted DNA <400> 5 aaguactuag cgtaag 16 <210> 6 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> PRNA-PNA-DNA chimera <220> <221> misc_feature <222> (1)..(2) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (3)..(3) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (4)..(10) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (11)..(11) <223> 5'-amino-substituted DNA <400> 6 tgcaagacta taagattc 18 <210> 7 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> PRNA-PNA-DNA chimera <220> <221> misc_feature <222> (1)..(7) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (8)..(8) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (9)..(10) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (11)..(11) <223> 5'-amino-substituted DNA <400> 7 tgcaagacta taagattc 18 <210> 8 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> PRNA-PNA-DNA chimera <220> <221> misc_feature <222> (1)..(7) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (8)..(8) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (9)..(10) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (11)..(11) <223> 5'-amino-substituted DNA <400> 8 tgcaagacta taagattcaa t 21 <210> 9 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> PRNA-PNA-DNA chimera <220> <221> misc_feature <222> (1)..(3) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (4)..(4) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (5)..(8) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (9)..(9) <223> 5'-amino-substituted DNA <400> 9 gtauatctcc ttctta 16 <210> 10 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> DNA-PRNA-PNA chimera <220> <221> misc_feature <222> (9)..(10) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (11)..(11) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (12)..(18) <223> peptide nucleic acid (PNA) <400> 10 tgcaagacta uaagattc 18 <210> 11 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> DNA-PRNA-PNA chimera <220> <221> misc_feature <222> (9)..(13) <223> peptide nucleic acid (PNA) <220> <221> misc_feature <222> (14)..(14) <223> peptide ribonucleic acid (PRNA) <220> <221> misc_feature <222> (15)..(16) <223> peptide nucleic acid (PNA) <400> 11 gtatatctcc ttcuta 16 <210> 12 <211> 18 <212> RNA <213> Artificial Sequence <220> <223> 5'-FAM-RNA <400> 12 gaaucuuaua gucuugca 18 <210> 13 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> anti-sense DNA <400> 13 tgcaagacta taagattc 18 <210> 14 <211> 16 <212> RNA <213> Artificial Sequence <220> <223> 5'-FAM-RNA <400> 14 uaagaaggag auauac 16 <210> 15 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> anti-sense DNA <400> 15 gtatatctcc ttctta 16

Claims

1. A method for cleaving a target nucleic acid for non-diagnostic and non-therapeutic purposes, which uses a chimeric molecule and ribonuclease H to cleave the target nucleic acid, The chimeric molecule is formed by the fusion of a first nucleic acid capable of binding to a target nucleic acid and a second nucleic acid capable of binding to the target nucleic acid and having an anionic main chain skeleton. The main chain backbone of the first nucleic acid is an amide backbone, The first nucleic acid is a combination of peptide ribonucleic acid and peptide nucleic acid, The second nucleic acid is DNA, The first nucleic acid is fused to the 5' end of the second nucleic acid, The complex consisting of the chimeric molecule and the target nucleic acid bound to the chimeric molecule specifically binds to RNase H, The ribonuclease H cleaves the target nucleic acid at the fusion portion of the first nucleic acid and the second nucleic acid, The melting temperature Tm of the two target nucleic acid fragments after cleavage with the ribonuclease H is 38° C. or less.

2. The cutting method according to claim 1, in, The main chain backbone of the first nucleic acid is neutral.

3. The cutting method according to claim 1 or 2, in, The target nucleic acid is RNA.